{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:12:36Z","timestamp":1793646756676,"version":"4.5.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>During COVID-19, the Substance Abuse and Mental Health Services Administration (SAMHSA) allowed Methadone Maintenance Treatment (MMT) programs to relax in-person MMT requirements to reduce COVID-19 exposure. This study examines patient-reported changes to in-person methadone clinic attendance requirements during COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From June 7, 2020, to July 15, 2020, a convenience sample of methadone patients (<jats:italic>N<\/jats:italic>\u2009=\u2009392) were recruited in collaboration with  National Survivors Union (NSU) in 43 states and Washington D.C. through social media (Facebook, Reddit, Twitter, and Web site pop-ups). The community-driven research (CDR) online survey collected information on how patient take-home methadone dosing and in-person drug testing, counseling, and clinic visit frequency changed prior to COVID-19 (before March 2020) to during COVID-19 (June and July 2020).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the study time period, the percentage of respondents receiving at least 14\u00a0days of take-home doses increased from 22 to 53%, while the percentage receiving one or no take-home doses decreased from 22.4% before COVID-19 to 10.2% during COVID-19. In-person counseling attendance decreased from 82.9% to 19.4%. While only 3.3% of respondents accessed counseling through telehealth before COVID-19, this percentage increased to 61.7% during COVID-19. Many respondents (41.3%) reported visiting their clinics in person once a week or more during COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>During the first wave of COVID-19, methadone patients report decreased in-person clinic attendance and increased take-home doses and use of telehealth for counseling services. However, respondents reported considerable variations, and many were still required to make frequent in-person clinic visits, which put patients at risk of COVID-19 exposure. Relaxations of MMT in-person requirements during COVID-19 should be consistently implemented and made permanent, and patient experiences of these changes should be explored further.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-023-00756-3","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T05:03:15Z","timestamp":1678338195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey"],"prefix":"10.1186","volume":"20","author":[{"given":"Sarah","family":"Brothers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Palayew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caty","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knina","family":"Strichartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Voyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"756_CR1","unstructured":"Ahmad F, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2020. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Reviewed November 12, 2020."},{"issue":"1","key":"756_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7326\/M20-1141","volume":"173","author":"GC Alexander","year":"2020","unstructured":"Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Annals Int Med. 2020;173(1):57\u20138. https:\/\/doi.org\/10.7326\/M20-1141.","journal-title":"Annals Int Med"},{"key":"756_CR3","unstructured":"Alter A, & Yeager C (2020) COVID-19 Impact on US national overdose crisis. University of Baltimore. Baltimore: ODMAP. Retrieved July 12, 2020."},{"issue":"5","key":"756_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1176\/appi.ps.202000534","volume":"72","author":"J Baillargeon","year":"2021","unstructured":"Baillargeon J, Polychronopoulou E, Kuo YF, Raji MA. The impact of substance use disorder on COVID-19 outcomes. Psychiatr Serv. 2021;72(5):578\u201381.","journal-title":"Psychiatr Serv"},{"issue":"4","key":"756_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0740-5472(03)00188-0","volume":"25","author":"K Beardsley","year":"2003","unstructured":"Beardsley K, Wish ED, Fitzelle DB, O\u2019Grady K, Arria AM. Distance traveled to outpatient drug treatment and client retention. J Subst Abuse Treat. 2003;25(4):279\u201385.","journal-title":"J Subst Abuse Treat"},{"key":"756_CR6","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1210","author":"WC Becker","year":"2020","unstructured":"Becker WC, Fiellin DA. When epidemics collide: Coronavirus disease 2019 (COVID-19) and the opioid crisis. Publ Online. 2020. https:\/\/doi.org\/10.7326\/M20-1210.","journal-title":"Publ Online"},{"issue":"2","key":"756_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.drugalcdep.2003.12.009","volume":"74","author":"RE Booth","year":"2004","unstructured":"Booth RE, Corsi KF, Mikulich-Gilbertson SK. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend. 2004;74(2):177\u201385.","journal-title":"Drug Alcohol Depend"},{"key":"756_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108449","volume":"131","author":"S Brothers","year":"2021","unstructured":"Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. J Substan Abuse Treat. 2021;131:108449","journal-title":"J Substan Abuse Treat"},{"issue":"8","key":"756_CR9","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.2105\/AJPH.2007.125757","volume":"98","author":"JS Carrera","year":"2008","unstructured":"Carrera JS, Key K, Bailey S, Hamm JA, Cuthbertson CA, Lewis EY, et al. Community science as a pathway for resilience in response to a public health crisis in Flint, Michigan. Soc Sci. 2019;8(3), 94.","journal-title":"Am J Public Health."},{"key":"756_CR10","doi-asserted-by":"publisher","unstructured":"Chen K L, Brozen M, Rollman J E, Ward T, Norris K, Gregory K D, & Zimmerman F J (2020) Transportation access to health care during the COVID-19 pandemic: trends and implications for significant patient populations and health care needs. Los Angeles, CA: UCLA Institute of transportation studies. Report No.: UC-ITS-2021\u201311 | https:\/\/doi.org\/10.17610\/T6RK5N. Accessed Oct 30, 2020.","DOI":"10.17610\/T6RK5N"},{"issue":"8","key":"756_CR11","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.2105\/AJPH.2007.125757","volume":"98","author":"S Christopher","year":"2008","unstructured":"Christopher S, Watts V, McCormick AKHG, Young S. Building and maintaining trust in a community-based participatory research partnership. Am J Public Health. 2008;98(8):1398\u2013406.","journal-title":"Am J Public Health."},{"issue":"3","key":"756_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/08897077.2020.1787300","volume":"41","author":"G Cochran","year":"2020","unstructured":"Cochran G, Bruneau J, Cox N, Gordon AJ. Medication treatment for opioid use disorder and community pharmacy: expanding care during a national epidemic and global pandemic. Substance Abuse. 2020;41(3):269\u201374.","journal-title":"Substance Abuse"},{"issue":"2","key":"756_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63\u201375.","journal-title":"Harv Rev Psychiatry"},{"key":"756_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000679","author":"CS Davis","year":"2020","unstructured":"Davis CS, Samuels EA. Opioid policy changes during the COVID-19 pandemic-and beyond. J Addict Med. 2020. https:\/\/doi.org\/10.1097\/ADM.0000000000000679.","journal-title":"J Addict Med"},{"issue":"1","key":"756_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","volume":"106","author":"L Degenhardt","year":"2011","unstructured":"Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32\u201351.","journal-title":"Addiction"},{"issue":"12","key":"756_CR16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, Whiteford H, Leung J, Naghavi M, Griswold M, Rehm J. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Psychiatr. 2018;5(12):987\u20131012.","journal-title":"Lancet Psychiatr"},{"issue":"7773","key":"756_CR17","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/d41586-019-02682-6","volume":"573","author":"L Drew","year":"2019","unstructured":"Drew L. Opioids by the numbers. Nature. 2019;573(7773):S2-s3.","journal-title":"Nature"},{"issue":"2","key":"756_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/ADM.0000000000000193","volume":"10","author":"K Dugosh","year":"2016","unstructured":"Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):91.","journal-title":"J Addict Med"},{"key":"756_CR19","doi-asserted-by":"publisher","first-page":"117822182210855","DOI":"10.1177\/11782218221085590","volume":"16","author":"C Ezie","year":"2022","unstructured":"Ezie C, Badolato R, Rockas M, Nafiz R, Sands B, Wolkin A, Farahmand P. COVID 19 and the opioid epidemic: an analysis of clinical outcomes during COVID 19. Substance Abuse Res Treat. 2022;16:11782218221085590. https:\/\/doi.org\/10.1177\/11782218221085590.","journal-title":"Substance Abuse Res Treat"},{"key":"756_CR20","unstructured":"Facher L (2022) Top US addiction researcher calls for broad deregulation of methadone. STAT. https:\/\/www.statnews.com\/2022\/11\/16\/nora-volkow-nida-broad-deregulation-methadone\/"},{"key":"756_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108276","volume":"123","author":"MC Figgatt","year":"2021","unstructured":"Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021;123: 108276.","journal-title":"J Subst Abuse Treat"},{"key":"756_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s11524-020-00484-0","volume":"97","author":"N Glober","year":"2020","unstructured":"Glober N, Mohler G, Huynh P, Arkins T, O\u2019Donnell D, Carter J, Ray B. Impact of COVID-19 pandemic on drug overdoses in Indianapolis. J Urban Health. 2020;97:802\u20137.","journal-title":"J Urban Health"},{"key":"756_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109049","volume":"228","author":"LA Goldsamt","year":"2021","unstructured":"Goldsamt LA, Rosenblum A, Appel P,Paris P, Nazia N. The impact of COVID-19 on opioid treatment programs in the United States. Drug Alcohol Depend. 2021;228:109049.","journal-title":"Drug Alcohol Depend"},{"key":"756_CR24","doi-asserted-by":"crossref","unstructured":"Hansen H, Roberts SK. Two tiers of biomedicalization: Methadone, buprenorphine, and the racial politics of addiction treatment. In: Critical perspectives on addiction, vol. 14. Emerald Group Publishing Limited; 2012. p. 79\u2013102.","DOI":"10.1108\/S1057-6290(2012)0000014008"},{"issue":"135","key":"756_CR25","doi-asserted-by":"publisher","first-page":"108655","DOI":"10.1016\/j.jsat.2021.108655","volume":"1","author":"MT Harris","year":"2022","unstructured":"Harris MT, Lambert AM, Maschke AD, Bagley SM, Walley AY, Gunn CM. \u201cNo home to take methadone to\u201d: experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. J Substance Abuse Treatment. 2022;1(135):108655. https:\/\/doi.org\/10.1016\/j.jsat.2021.108655.","journal-title":"J Substance Abuse Treatment"},{"key":"756_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108223","volume":"124","author":"MA Hatch-Maillette","year":"2021","unstructured":"Hatch-Maillette MA, Peavy KM, Tsui JI, Banta-Green CJ, Woolworth S, Grekin P. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: provider perspectives. J Subst Abuse Treat. 2021;124: 108223.","journal-title":"J Subst Abuse Treat"},{"key":"756_CR27","doi-asserted-by":"crossref","unstructured":"Hedegaard H, Mini\u00f1o A M, & Warner M (2020) Drug overdose deaths in the United States, 1999-2018. Atlanta, GA: National center for health statistics. NCHS Data Brief No. 356. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db356-h.pdf. Last accessed Oct 30, 2020.","DOI":"10.15620\/cdc:112340"},{"issue":"4","key":"756_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11524-020-00465-3","volume":"97","author":"R Heimer","year":"2020","unstructured":"Heimer R, McNeil R, Vlahov D. A community responds to the COVID-19 pandemic: a case study in protecting the health and human rights of people who use drugs. J Urban Health. 2020;97(4):448\u201356.","journal-title":"J Urban Health"},{"issue":"141","key":"756_CR29","doi-asserted-by":"publisher","first-page":"108801","DOI":"10.1016\/j.jsat.2022.108801","volume":"1","author":"KA Hoffman","year":"2022","unstructured":"Hoffman KA, Foot C, Levander XA, Cook R, Terashima JP, McIlveen JW, Korthuis PT, McCarty D. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: a mixed methods analysis. J Substance Abuse Treatment. 2022;1(141):108801. https:\/\/doi.org\/10.1016\/j.jsat.2022.108801.","journal-title":"J Substance Abuse Treatment"},{"key":"756_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108288","volume":"124","author":"SB Hunter","year":"2021","unstructured":"Hunter SB, Dopp AR, Ober AJ, Uscher-Pines L. Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: a qualitative study. J Subst Abuse Treat. 2021;124: 108288.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"756_CR31","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","volume":"70","author":"JH Jaffe","year":"2003","unstructured":"Jaffe JH, O\u2019Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2):S3\u201311.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"756_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","volume":"79","author":"CM Jones","year":"2022","unstructured":"Jones CM, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-involved overdose deaths in the us before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. JAMA Psychiat. 2022;79(9):932\u20134.","journal-title":"JAMA Psychiat"},{"key":"756_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108219","volume":"122","author":"G Joseph","year":"2021","unstructured":"Joseph G, Torres-Lockhart K, Stein MR, Mund PA, Nahvi S. Reimagining patient-centered care in opioid treatment programs: lessons from the Bronx during COVID-19. J Subst Abuse Treat. 2021;122: 108219.","journal-title":"J Subst Abuse Treat"},{"issue":"2\u20133","key":"756_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.drugalcdep.2011.01.008","volume":"117","author":"SM Kelly","year":"2011","unstructured":"Kelly SM, O\u2019Grady KE, Mitchell SG, Brown BS, Schwartz RP. Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend. 2011;117(2\u20133):170\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"756_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","volume":"161","author":"G Kourounis","year":"2016","unstructured":"Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"92","key":"756_CR36","doi-asserted-by":"publisher","first-page":"103140","DOI":"10.1016\/j.drugpo.2021.103140","volume":"1","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Bunting AM, Frank D, Arshonsky J, Gu Y, Friedman SR, Bragg MA. \u201cHow will I get my next week\u2019s script?\u201d Reactions of reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic. Int J Drug Policy. 2021;1(92):103140.","journal-title":"Int J Drug Policy"},{"key":"756_CR37","series-title":"New Medications for Drug Abuse","first-page":"186","volume-title":"Annals of the New York Academy of Sciences","author":"MJ Kreek","year":"2000","unstructured":"Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research, and future in mainstream medicine. In: Glick SD, Maisonneuve IM, editors. Annals of the New York Academy of Sciences, vol. 909. New Medications for Drug Abuse. New York, NY: New York Academy of Sciences; 2000. p. 186\u2013216."},{"issue":"1","key":"756_CR38","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/08897077.2021.1986768","volume":"43","author":"XA Levander","year":"2022","unstructured":"Levander XA, Pytell JD, Stoller KB, Korthuis PT, Chander G. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Substance abuse. 2022;43(1):633\u20139. https:\/\/doi.org\/10.1080\/08897077.2021.1986768.","journal-title":"Substance abuse"},{"key":"756_CR39","doi-asserted-by":"publisher","first-page":"108544","DOI":"10.1016\/j.jsat.2021.108544","volume":"133","author":"C Lin","year":"2022","unstructured":"Lin C, Clingan SE, Cousins SJ, Valdez J, Mooney LJ, Hser YI. The impact of COVID-19 on substance use disorder treatment in California: service providers\u2019 perspectives. J Substance Abuse Treatment. 2022;133:108544. https:\/\/doi.org\/10.1016\/j.jsat.2021.108544.","journal-title":"J Substance Abuse Treatment"},{"issue":"241","key":"756_CR40","doi-asserted-by":"publisher","first-page":"109678","DOI":"10.1016\/j.drugalcdep.2022.109678","volume":"1","author":"NA Livingston","year":"2022","unstructured":"Livingston NA, Davenport M, Head M, Henke R, LeBeau LS, Gibson TB, Banducci AN, Sarpong A, Jayanthi S, Roth C, Camacho-Cook J. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): a nationwide veterans health administration cohort study. Drug Alcohol Dependence. 2022;1(241):109678.","journal-title":"Drug Alcohol Dependence"},{"issue":"3","key":"756_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0955-3959(00)00047-5","volume":"11","author":"L Luger","year":"2000","unstructured":"Luger L, Bathia N, Alcorn R, Power R. Involvement of community pharmacists in the care of drug misusers: pharmacy-based supervision of methadone consumption. I J Drug Policy. 2000;11(3):227\u201334.","journal-title":"I J Drug Policy"},{"key":"756_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109100","volume":"228","author":"EF Madden","year":"2021","unstructured":"Madden EF, Christian BT, Lagisetty PA, Ray BR, Sulzer SH. Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug Alcohol Depend. 2021;228:109100.","journal-title":"Drug Alcohol Depend."},{"key":"756_CR43","doi-asserted-by":"publisher","first-page":"110070","DOI":"10.1016\/j.pnpbp.2020.110070","volume":"106","author":"J Mallet","year":"2020","unstructured":"Mallet J, Dubertret C, Le Strat Y. Addictions in the COVID-19 era: current evidence, future perspectives a comprehensive review. Progress Neuro-Psychopharmacol Biol Psychiatry. 2020;106:110070.","journal-title":"Progress Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"6","key":"756_CR44","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/ADM.0000000000000812","volume":"15","author":"JW McIlveen","year":"2021","unstructured":"McIlveen JW, Hoffman K, Priest KC, Choi D, Korthuis PT, McCarty D. Reduction in oregon's medication dosing visits After the SARS-CoV-2 relaxation of restrictions on take-home medication. J Addict Med. 2021;15(6):516.","journal-title":"J Addict Med."},{"issue":"10","key":"756_CR45","doi-asserted-by":"publisher","first-page":"e0274094","DOI":"10.1371\/journal.pone.0274094","volume":"17","author":"BE Meyerson","year":"2022","unstructured":"Meyerson BE, Bentele KG, Russell DM, Brady BR, Downer M, Garcia RC, Garnett I, Lutz R, Mahoney A, Samorano S, Arredondo C, Andres HJ, Coles H, Granillo B. Nothing really changed: arizona patient experience of methadone and buprenorphine access during COVID. PLoS ONE. 2022;17(10):e0274094.","journal-title":"PLoS ONE"},{"issue":"9","key":"756_CR46","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1111\/j.1360-0443.2010.02992.x","volume":"105","author":"PG Miller","year":"2010","unstructured":"Miller PG, S\u00f8nderlund AL. Using the internet to research hidden populations of illicit drug users: a review. Addiction. 2010;105(9):1557\u201367.","journal-title":"Addiction"},{"issue":"7","key":"756_CR47","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1177\/1049732311403500","volume":"21","author":"MJ Montoya","year":"2011","unstructured":"Montoya MJ, Kent EE. Dialogical action: moving from community-based to community-driven participatory research. Qual Health Res. 2011;21(7):1000\u201311.","journal-title":"Qual Health Res"},{"key":"756_CR48","unstructured":"NIDA. (2019). Overdose death rates. https:\/\/www.drugabuse.gov\/relatedtopics\/trends-statistics\/overdose-death-rates. Updated January 2019. Accessed Oct 29, 2020."},{"issue":"5","key":"756_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS ONE. 2020;15(5): e0232086.","journal-title":"PLoS ONE"},{"issue":"10","key":"756_CR50","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2105\/AJPH.2018.304590","volume":"108","author":"AL Pitt","year":"2018","unstructured":"Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health. 2018;108(10):1394\u2013400.","journal-title":"Am J Public Health"},{"key":"756_CR51","unstructured":"SAMHSA. (2020a). FAQs: Provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. Rockville, MD: Substance Abuse and mental health services administration. https:\/\/www.samhsa.gov\/sites\/default\/files\/faqs-for-oud-prescribing-and-dispensing.pdf. Last accessed Oct 28, 2020."},{"key":"756_CR52","unstructured":"SAMHSA (2020b) Key substance use and mental health indicators in the United States: Results from the 2019 National survey on drug use and health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for behavioral health statistics and quality, substance abuse and mental health services administration. Retrieved from https:\/\/www.samhsa.gov\/data\/"},{"key":"756_CR53","unstructured":"SAMHSA (2020c). National survey of substance abuse treatment services (N-SSATS): 2019. Data on substance abuse treatment facilities. Rockville, Substance abuse and mental health services administration."},{"key":"756_CR54","unstructured":"SAMHSA (2023) Methadone take-home flexibilities extension guidance. Retrieved from https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/methadone-guidance. Last accessed Feb 2, 2023."},{"key":"756_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103537","volume":"101","author":"B Saloner","year":"2022","unstructured":"Saloner B, Krawczyk N, Solomon K, Allen ST, Morris M, Haney K, Sherman SG. Experiences with substance use disorder treatment during the COVID-19 pandemic: findings from a multistate survey. Int J Drug Policy. 2022;101: 103537.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"756_CR56","first-page":"CD011983","volume":"4","author":"R Saulle","year":"2017","unstructured":"Saulle R, Vecchi S, Gowing L. Supervised dosing with a long-acting opioid medication in the management of opioid dependence. Cochrane Database Syst Rev. 2017;4(4):CD011983.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"756_CR57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/ADT.0000000000000099","volume":"16","author":"RH Shakira","year":"2017","unstructured":"Shakira RH, W., Sarimah, A., & Norsa\u2019adah, B. Factor predictive of 1-year retention on methadone maintenance therapy program: a survival analysis study. Addict Disord Treat. 2017;16(2):64\u20139.","journal-title":"Addict Disord Treat"},{"key":"756_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103364","volume":"98","author":"C Simon","year":"2021","unstructured":"Simon C, Brothers S, Strichartz K, Coulter A, Voyles N, Herdlein A, Vincent L. We are the researched, the researchers, and the discounted: the experiences of drug user activists as researchers. Int J Drug Policy. 2021;98:103364.","journal-title":"Int J Drug Policy."},{"key":"756_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108047","author":"AK Slaunwhite","year":"2020","unstructured":"Slaunwhite AK, Gan WQ, Xavier C, Zhao B, Buxton JA, Desai R. Overdose and risk factors for severe acute respiratory syndrome. Drug and Alcohol Dependence, Publ Online. 2020. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108047.","journal-title":"Drug and Alcohol Dependence, Publ Online"},{"key":"756_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108176","author":"S Slavova","year":"2020","unstructured":"Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Dependence Publ Online. 2020. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108176.","journal-title":"Drug Alcohol Dependence Publ Online"},{"key":"756_CR61","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:1550.","journal-title":"BMJ"},{"key":"756_CR62","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000320576","volume":"17","author":"H Stover","year":"2011","unstructured":"Stover H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011;17:44\u201354.","journal-title":"Eur Addict Res."},{"issue":"1","key":"756_CR63","first-page":"1143","volume":"43","author":"LW Suen","year":"2021","unstructured":"Suen LW, Castellanos S, Joshi N, Satterwhite S, Knight KR. \u201cThe idea is to help people achieve greater success and liberty\u201d: a qualitative study of expanded methadone take-home access in opioid use disorder treatment. Substance abuse. 2021;43(1):1143.","journal-title":"Substance abuse"},{"issue":"1","key":"756_CR64","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/08897077.2022.2060438","volume":"43","author":"LW Suen","year":"2022","unstructured":"Suen LW, Castellanos S, Joshi N, Satterwhite S, Knight KR. \u201cThe idea is to help people achieve greater success and liberty\u201d: a qualitative study of expanded methadone take-home access in opioid use disorder treatment. Substance Abuse. 2022;43(1):1143\u201350.","journal-title":"Substance Abuse"},{"issue":"S2","key":"756_CR65","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.2105\/AJPH.2021.306654","volume":"112","author":"LW Suen","year":"2022","unstructured":"Suen LW, Coe WH, Wyatt JP, Adams ZM, Gandhi M, Batchelor HM, Castellanos S, Joshi N, Satterwhite S, P\u00e9rez-Rodr\u00edguez R, Rodr\u00edguez-Guerra E, Albizu-Garcia CE, Knight KR, Jordan A. Structural adaptations to methadone maintenance treatment and take-home dosing for opioid use disorder in the era of COVID-19. Am J Public Health. 2022;112(S2):S112\u20136. https:\/\/doi.org\/10.2105\/AJPH.2021.306654.","journal-title":"Am J Public Health"},{"key":"756_CR66","doi-asserted-by":"publisher","first-page":"108514","DOI":"10.1016\/j.jsat.2021.108514","volume":"132","author":"PC Treitler","year":"2022","unstructured":"Treitler PC, Bowden CF, Lloyd J, Enich M, Nyaku AN, Crystal S. Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms. J Substance Abuse Treat. 2022;132:108514.","journal-title":"J Substance Abuse Treat"},{"key":"756_CR67","unstructured":"US Census Bureau. (2010). Census regions and divisions of the United States. US Census Bureau website."},{"issue":"7","key":"756_CR68","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1080\/10826084.2022.2064509","volume":"57","author":"SM Walters","year":"2022","unstructured":"Walters SM, Perlman DC, Guarino H, Mateu-Gelabert P, Frank D. Lessons from the first wave of COVID-19 for improved medications for opioid use disorder (MOUD) treatment: benefits of easier access, extended take homes, and new delivery modalities. Subst Use Misuse. 2022;57(7):1144\u201353. https:\/\/doi.org\/10.1080\/10826084.2022.2064509.","journal-title":"Subst Use Misuse"},{"key":"756_CR69","doi-asserted-by":"publisher","first-page":"103591","DOI":"10.1016\/j.drugpo.2022.103591","volume":"102","author":"C Welsh","year":"2022","unstructured":"Welsh C, Doyon S, Hart K. Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations. Int J Drug Policy. 2022;102:103591.","journal-title":"Int J Drug Policy"},{"key":"756_CR70","unstructured":"World health organization (WHO). Department of mental health, substance abuse, world health organization, international narcotics control board, united nations office on drugs, & crime. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, Switzerland: World Health Organization; 2009. https:\/\/www.who.int\/substance_abuse\/publications\/Opioid_dependence_guidelines.pdf. Accessed 30 Oct 2020."},{"key":"756_CR71","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","volume":"169","author":"LT Wu","year":"2016","unstructured":"Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117\u201327.","journal-title":"Drug Alcohol Depend"},{"issue":"S2","key":"756_CR72","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.2105\/AJPH.2022.306806","volume":"112","author":"JP Wyatt","year":"2022","unstructured":"Wyatt JP, Suen LW, Coe WH, Adams ZM, Gandhi M, Batchelor HM, Castellanos S, Joshi N, Satterwhite S, P\u00e9rez-Rodr\u00edguez R, Rodr\u00edguez-Guerra E, Albizu-Garcia CE, Knight KR, Jordan A. Federal and state regulatory changes to methadone take-home doses: impact of sociostructural factors. Am J Public Health. 2022;112(S2):S143\u20136. https:\/\/doi.org\/10.2105\/AJPH.2022.306806.","journal-title":"Am J Public Health"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00756-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00756-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00756-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T05:05:29Z","timestamp":1678338329000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00756-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00756-3","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"14 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yale University Institutional Review Board reviewed this study, which was determined to fall under the category of not human subjects research because it was not individually identifiable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}